ICU Sedation & Analgesia

ABPN Neurocritical Care Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Neurologic Examination & Coma Assessment in the ICU

Current Examination, Blueprint & Preparation Neurologic Examination in Critically Ill Patients Coma Evaluation & Consciousness Alterations Delirium & Toxic-Metabolic Encephalopathy in the ICU

2 Chapter 2: Cerebral Physiology & Intracranial Dynamics

Cerebral Blood Flow, Metabolism & Autoregulation Intracranial Pressure & Compliance Cerebral Edema & Herniation Syndromes

3 Chapter 3: Intracranial Hypertension & Cerebral Perfusion Management

Tiered ICP Management Protocols Hyperosmolar Therapy & Fluid Management Advanced & Refractory ICP Interventions

4 Chapter 4: Airway, Mechanical Ventilation & Pulmonary ICU Management

Emergency Airway Management & Neuro-Intubation Mechanical Ventilation Strategies in Acute Brain Injury Tracheostomy & Ventilator Weaning in Neurocritical Care Pulmonary Complications in the Neuro-ICU Obstructive Lung Disease, Pulmonary Hypertension & Bronchoscopy

5 Chapter 5: Hemodynamics, Shock & Cardiovascular Management

Hemodynamic Monitoring & Blood Pressure Targets Vasoactive Agents: Inotropes, Vasopressors & Antihypertensives Cardiac Complications of Brain Injury

6 Chapter 6: Neuropharmacology, Analgesia & Sedation

ICU Sedation & Analgesia Neuromuscular Blockade & Monitoring Propofol Infusion Syndrome & Drug Toxicities Antiseizure Drug Pharmacology in the ICU

7 Bleeding, Thrombosis & Hematologic Emergencies

Warfarin & Heparin Reversal Direct Oral Anticoagulant (DOAC) Reversal Antiplatelet Management & Platelet Dysfunction Venous Thromboembolism Prophylaxis & Management Transfusion, Coagulopathy, TMA & Cellular-Therapy Neurotoxicity

8 Chapter 8: Systemic ICU Care, Fluids, Electrolytes & Endocrine

Hyponatremia & Osmoregulation: SIADH vs Cerebral Salt Wasting Diabetes Insipidus, Hypernatremia & Endocrine Crises Critical Care Prophylaxis, Nutrition & Infection Prevention

9 Systemic Trauma & Environmental Injury

Polytrauma, Chest Injury & Abdominal Hemorrhage Burns, Electrical Injury & Hanging

10 Cardiac Emergencies & Mechanical Support

IABP, Ventricular Devices & ECMO Acute Coronary, Valvular, Rhythm & Aortic Emergencies

11 Kidney Injury, Acid–Base & Renal Replacement

Acute Kidney Injury & Renal Drug Clearance Acid–Base Disorders, Electrolytes & Renal Replacement

12 Systemic Infection & Endocrine Emergencies

Sepsis, Endocarditis & Antimicrobial Principles Thyroid, Adrenal & Dysglycemic Emergencies

13 Gastrointestinal & Hepatic Emergencies

Acute Abdomen, GI Bleeding & Abdominal Compartment Syndrome Acute Liver Failure, Cirrhosis & Hepatic Drug Effects

14 Chapter 9: Neuroimaging in the Neuro-ICU

Non-Contrast CT & CT Angiography CT Perfusion & Advanced Perfusion Imaging Magnetic Resonance Imaging in Critical Illness

15 Chapter 10: Electrophysiology & Neuromonitoring

Continuous EEG & ACNS Standardized Critical Care Terminology Invasive Neuromonitoring: ICP & External Ventricular Drains Multimodal Monitoring: PbtO2, Microdialysis & Transcranial Doppler

16 Angiography, Electrodiagnosis & CSF Analysis

Conventional Angiography & Cranial–Spinal Shunts EMG, Nerve Conduction & Acute Muscle Disease CSF Analysis: Infection, Inflammation & Hemorrhage

17 Chapter 11: Bedside Procedures, Ultrasound & Death by Neurologic Criteria

Critical Care Procedural Skills Critical Care Ultrasound & Echocardiography Determination of Death by Neurologic Criteria

18 Chapter 12: Acute Ischemic Stroke & Reperfusion Therapies

Acute Ischemic Stroke Management & Thrombolysis Endovascular Thrombectomy & Large Vessel Occlusion Malignant Hemispheric & Cerebellar Infarction

19 Chapter 13: Spontaneous Intracerebral Hemorrhage & Intraventricular Hemorrhage

Acute Intraparenchymal Hemorrhage Management Intraventricular Hemorrhage & Hydrocephalus Surgical Evacuation & Minimally Invasive Surgery in ICH

20 Chapter 14: Aneurysmal Subarachnoid Hemorrhage & Delayed Cerebral Ischemia

Aneurysmal Subarachnoid Hemorrhage: Acute Resuscitation & Securing Delayed Cerebral Ischemia & Cerebral Vasospasm Non-Aneurysmal Subarachnoid Hemorrhage & Vascular Malformations

21 Venous, Spinal & Traumatic Vascular Disease

Cerebral Venous Thrombosis & Spinal Cord Infarction Traumatic Dissection, Carotid–Cavernous Fistula & Penetrating Injury

22 Chapter 15: Traumatic Brain & Spinal Cord Injury

Severe Traumatic Brain Injury & Contusions Acute Traumatic Spinal Cord Injury & Neurogenic Shock Spine Trauma, Fractures & Cord Syndromes

23 Chapter 16: Status Epilepticus, Seizures & Neuromuscular Emergencies

Status Epilepticus: Convulsive & Non-Convulsive Refractory & Super-Refractory Status Epilepticus Acute Neuromuscular Respiratory Failure

24 Chapter 17: Post-Cardiac Arrest Care, CNS Infections & Encephalitis

Targeted Temperature Management & Post-Cardiac Arrest Care Post-Cardiac Arrest Neuroprognostication Acute CNS Infections, Encephalitis & Inflammatory Emergencies

25 Neuroinflammation & Neurooncology

Fulminant Demyelination & Autoimmune Encephalitis Brain, Spinal & Leptomeningeal Cancer Emergencies

26 Pregnancy, Transplantation & Pediatric Care

Pregnancy, Postpartum & Post-Transplant Neurologic Care Pediatric Neurocritical Care

27 Chapter 18: Neurosurgical & Perioperative Emergencies

Postoperative Neurosurgical Complications Device Complications: EVDs, Shunts & ICP Monitors Cerebral Hyperperfusion Syndrome & Post-Interventional Emergencies

28 Chapter 19: Ethics, Palliative Care & Organ Donation in the Neuro-ICU

Communication, Surrogate Decision-Making & Conflict Resolution Neuroprognostication Ethics, Withdrawal of Life Support & Palliative Care Organ Donation & Management of the Deceased Donor

ICU Sedation & Analgesia

Key Takeaways Explain This Topic AI

Neuro-ICU analgosedation prioritizes blunting intracranial pressure (ICP) spikes, preventing ventilator dyssynchrony, and preserving reliable windows for serial neurologic examinations.

The Richmond Agitation-Sedation Scale (RASS) guides titration: light sedation (-1 to 0) minimizes delirium and shortens ventilation, whereas deep sedation (-4 to -5) is reserved for acute intracranial hypertension and targeted temperature management.

Propofol reduces cerebral metabolic rate of oxygen (CMRO2) and cerebral blood flow (CBF) in parallel, providing rapid onset and offset, but carries risks of systemic vasodilation, myocardial depression, and propofol infusion syndrome.

Dexmedetomidine provides non-GABAergic, opioid-sparing sedation mediated by central alpha-2 adrenoreceptors in the locus coeruleus, facilitating interactive wakefulness and lower delirium rates with relatively preserved respiratory drive; respiratory depression or airway events can still occur, particularly with other drugs.

Remifentanil possesses a fixed context-sensitive half-time of 3 to 5 minutes due to non-specific tissue esterase metabolism, making it ideal for frequent wake-up trials, in stark contrast to fentanyl which accumulates in adipose tissue over prolonged infusions.

Last updated: October 2026

ICU Sedation & Analgesia

In the neurointensive care unit, analgosedation is not merely a supportive measure for comfort; it serves as an active neuromonitoring and neurotherapeutic intervention. Injudicious sedation obscures acute neurologic deterioration, delays recognition of intracranial catastrophes, prolongs mechanical ventilation, and induces delirium. Conversely, inadequate sedation precipitates severe intracranial pressure ( I C P ICP I CP ) crises, ventilator dyssynchrony, elevated intrathoracic pressure, hypertensive hemorrhage, and metabolic exhaustion. Achieving the optimal balance requires precision pharmacology tailored to cerebral hemodynamics, metabolic coupling, and serial examination demands.

Clinical Goals & Validated ICU Scoring Scales

The primary clinical objectives of analgosedation in neurocritical care comprise:

ICP Blunting & Neurometabolic Suppression: Eliminating noxious tracheal stimulation, coughing, straining, and patient-ventilator dyssynchrony that drive acute thoracic venous congestion, impair internal jugular venous drainage, and elevate I C P ICP I CP .

Patient Comfort & Stress Reduction: Alleviating physical pain, anxiety, and sympathetic overdrive, thereby mitigating catecholamine-induced surges in mean arterial pressure ( M A P MAP M A P ) and cerebral hyperperfusion.

Facilitation of Serial Neurologic Examinations: Selecting agents with rapid, predictable pharmacokinetics that permit periodic "neurologic wake-up exams" to detect emergent structural or vascular decompensation.

Richmond Agitation-Sedation Scale (RASS)

The Richmond Agitation-Sedation Scale is a 10-point validated scale ranging from + 4 +4 + 4 (combative) to − 5 -5 − 5 (unarousable). In general medical-surgical ICUs, guidelines recommend light sedation (RASS − 1 to 0 -1\text{ to }0 − 1 to 0 ). In neurocritical care, target scores depend strictly on the underlying cerebral pathophysiology:

Target RASS Score Clinical Description Primary Neuro-ICU Indications

0 to − 1 0\text{ to }-1 0 to − 1 (Alert to Drowsy) Spontaneously awake, calm, sustained eye contact ( > 10 s > 10\text{ s} > 10 s ) to verbal call Recovering acute ischemic stroke, non-operative intracerebral hemorrhage, weaning from mechanical ventilation, extubation readiness

− 2 to − 3 -2\text{ to }-3 − 2 to − 3 (Light to Moderate) Briefly awakens with eye contact ( < 10 s < 10\text{ s} < 10 s ) or eye movement to voice Agitation risking catheter dislodgement, mild ventilator dyssynchrony, postoperative craniotomy without brain swelling

− 4 to − 5 -4\text{ to }-5 − 4 to − 5 (Deep to Unarousable) No response to voice; movement or no movement to physical stimulation Tier 2 intracranial hypertension ( I C P > 20 mmHg ICP > 20\text{ mmHg} I CP > 20 mmHg ), targeted temperature management (TTM), refractory status epilepticus ( R S E RSE RSE )

Note

Target RASS scores must be explicitly prescribed and titrated shift-by-shift. In patients without intracranial hypertension, maintaining light sedation (RASS − 1 to 0 -1\text{ to }0 − 1 to 0 ) significantly shortens time to extubation, reduces delirium rates, and accelerates neurorehabilitation.

Critical-Care Pain Observation Tool (CPOT)

Pain assessment in non-verbal or intubated patients requires behavioral scoring. The Critical-Care Pain Observation Tool evaluates four operational behaviors: facial expression ( 0 – 2 0\text{--}2 0 – 2 ), body movements ( 0 – 2 0\text{--}2 0 – 2 ), muscle tension via passive arm flexion ( 0 – 2 0\text{--}2 0 – 2 ), and ventilator compliance or vocalization ( 0 – 2 0\text{--}2 0 – 2 ). A total score > 2 > 2 > 2 indicates significant pain requiring analgesic titration before escalating sedative infusions.

• Sedative Pharmacology in Neurocritical Care Sedative Drug Mechanisms in the Neuro-ICU
• ├── GABA-A Receptor Agonists (Inhibitory Neurotransmission)
• │ ├── Propofol (Alkylphenol): Rapid onset/offset, decreases CBF & CMRO2, causes hypotension & PRIS
• │ └── Midazolam (Benzodiazepine): Lipophilic, active 1-hydroxymidazolam metabolite, deliriogenic
• ├── Central Alpha-2 Adrenoreceptor Agonist
• │ └── Dexmedetomidine: Locus coeruleus mediated, non-GABAergic, interactive wakefulness, bradycardia
• └── NMDA Receptor Antagonist

└── Ketamine: Inhibits glutamate, bronchodilatory, maintains MAP, preserves respiration, anti-spreading depression

Propofol

Mechanism: Alkylphenol derivative that potentiates gamma-aminobutyric acid ( G A B A A GABA_A G A B A A ​ ) receptor currents through allosteric β \beta β -subunit modulation and inhibits N M D A NMDA NM D A glutamate receptors.

Cerebral Hemodynamics: Coupled reduction in cerebral metabolic rate of oxygen ( C M R O 2 CMRO_2 CMR O 2 ​ ) and cerebral blood flow ( C B F CBF CBF ), preserving flow-metabolism coupling. It reduces intracranial blood volume and lowers I C P ICP I CP . At high doses, it induces burst suppression on electroencephalography ( E E G EEG EEG ).

Pharmacokinetics: Rapid onset ( 30 – 60 seconds 30\text{--}60\text{ seconds} 30 – 60 seconds ) with rapid initial redistribution ( t 1 / 2 α = 2 – 8 minutes t_{1/2\alpha} = 2\text{--}8\text{ minutes} t 1/2 α ​ = 2 – 8 minutes ). However, lipophilic accumulation during prolonged high-dose infusions increases its context-sensitive half-time.

Adverse Effects: Potent dose-dependent arterial vasodilation and direct myocardial depression, frequently precipitating systemic hypotension and compromising cerebral perfusion pressure ( C P P = M A P − I C P CPP = MAP - ICP CPP = M A P − I CP ). Formulated in a 10 % 10\% 10% lipid emulsion ( 1.1 kcal/mL 1.1\text{ kcal/mL} 1.1 kcal/mL ), which requires counting toward nutritional calories and monitoring for hypertriglyceridemia, pancreatitis, and Propofol Infusion Syndrome ( P R I S PRIS PR I S ).

Dexmedetomidine

Mechanism: Highly selective centrally acting α 2 \alpha_2 α 2 ​ -adrenergic agonist ( α 2 : α 1 \alpha_2:\alpha_1 α 2 ​ : α 1 ​ receptor binding ratio 1620 : 1 1620:1 1620 : 1 ). It acts on presynaptic α 2 \alpha_2 α 2 ​ receptors in the locus coeruleus of the pons, inhibiting noradrenergic neurotransmission and disinhibiting the ventrolateral preoptic nucleus ( V L P O VLPO V L PO ), producing an arousable sleep-like state, without equating it to a fixed normal sleep stage.

Cerebral Hemodynamics: Modest reduction in C B F CBF CBF via direct cerebral vasoconstriction without depressing C M R O 2 CMRO_2 CMR O 2 ​ . Preserves autoregulation and cerebrovascular reactivity to C O 2 CO_2 C O 2 ​ .

Clinical Profile: Promotes "interactive wakefulness," allowing patients to follow commands and participate in neurologic examinations during active infusion. It generally preserves respiratory drive better than many sedatives, but airway and breathing still require monitoring, facilitating extubation without sedative discontinuation. It significantly lowers ICU delirium incidence compared to GABAergic sedatives.

Adverse Effects: Centrally mediated sympatholysis causes sinus bradycardia and systemic hypotension. Rapid loading boluses paradoxically cause transient peripheral vasoconstriction and hypertension via vascular smooth muscle α 2 B \alpha_{2B} α 2 B ​ receptors, followed by prolonged hypotension; hence, loading boluses are strictly avoided in neurocritical care.

Midazolam

Mechanism: Imidazole-ring benzodiazepine that binds to the α / γ \alpha/\gamma α / γ subunit interface of G A B A A GABA_A G A B A A ​ receptors, increasing chloride channel opening frequency.

Pharmacokinetics & Pitfalls: Water-soluble at acidic ampoule pH ( p H < 4 pH < 4 p H < 4 ), but highly lipophilic at physiologic pH, enabling rapid central nervous system entry. However, midazolam undergoes hepatic CYP3A4/5 metabolism into an active metabolite, 1-hydroxymidazolam , which is cleared renally as a glucuronide. In critical illness, renal dysfunction, sepsis, or obesity, 1-hydroxymidazolam and parent drug accumulate extensively in peripheral adipose tissues, leading to prolonged, unpredicted coma lasting days after infusion cessation.

Neuro-ICU Role: Strongly deliriogenic; routine use is discouraged except for refractory status epilepticus, targeted temperature management with severe shivering, or hemodynamic instability refractory to propofol.

Ketamine

Mechanism: Non-competitive N N N -methyl- D D D -aspartate ( N M D A NMDA NM D A ) receptor antagonist that binds the phencyclidine site within the calcium channel pore, blocking glutamate-mediated excitotoxicity.

Cerebral Hemodynamics & Paradigm Shift: Historically avoided in head injury based on outdated animal models showing increased I C P ICP I CP . Modern clinical trials demonstrate that under controlled normocapnic mechanical ventilation, ketamine does not elevate I C P ICP I CP and maintains C P P CPP CPP by preserving cardiac output and mean arterial pressure through central sympathetic stimulation.

Neuroprotective Properties: Ketamine inhibits cortical spreading depolarizations ( C S D s CSDs CS Ds ), waves of cellular depolarization that drive secondary ischemic injury in traumatic brain injury ( T B I TBI TB I ) and subarachnoid hemorrhage ( S A H SAH S A H ). It provides potent somatic and visceral analgesia with relatively preserved respiratory drive; respiratory depression or airway events can still occur, particularly with other drugs.

Sedative Agent Primary Target Effect on C B F CBF CBF Effect on C M R O 2 CMRO_2 CMR O 2 ​ Impact on M A P MAP M A P / C P P CPP CPP Ideal Clinical Context in Neuro-ICU

Propofol G A B A A GABA_A G A B A A ​ agonist ↓ ↓ \downarrow\downarrow ↓↓ ↓ ↓ \downarrow\downarrow ↓↓ ↓ ↓ M A P \downarrow\downarrow MAP ↓↓ M A P , risk of ↓ C P P \downarrow CPP ↓ CPP Acute I C P ICP I CP elevation, status epilepticus, rapid neuro-exam checks

Dexmedetomidine α 2 \alpha_2 α 2 ​ agonist ↓ \downarrow ↓ Neutral / Slight ↓ \downarrow ↓ ↓ M A P \downarrow MAP ↓ M A P , ↓ H R \downarrow HR ↓ H R Non-intubated agitation, delirium weaning, cooperative neuro exams

Midazolam G A B A A GABA_A G A B A A ​ agonist ↓ \downarrow ↓ ↓ \downarrow ↓ Neutral to ↓ M A P \downarrow MAP ↓ M A P Refractory status epilepticus, shock states intolerant to propofol

Ketamine N M D A NMDA NM D A antagonist Neutral / ↑ \uparrow ↑ Neutral Maintained / ↑ M A P \uparrow MAP ↑ M A P Bronchospasm, shock, analgosedation, blunting spreading depolarizations

Analgesic Pharmacology: Opioids in Neurocritical Care

Pain and noxious stimuli trigger intense autonomic discharges, causing paroxysmal hypertension, tachycardia, intracranial venous hypertension, and secondary brain injury. An "analgesia-first" (analgosedation) paradigm reduces overall sedative requirements. Context-Sensitive Half-Time Profiles with Increasing Infusion Duration

• Remifentanil: ── 3-5 min (Flat, Organ-Independent Clearance) ──────────────────
• Hydromorphone: ── Slow increase (Moderate Hepatic Glucuronidation) ─────────────
• Fentanyl: ── Steep non-linear rise after 2-4 hours (Deep Adipose Saturation) ────
• Fentanyl

Synthetic phenylpiperidine μ \mu μ -opioid agonist. Highly lipophilic with rapid onset ( 1 – 2 minutes 1\text{--}2\text{ minutes} 1 – 2 minutes ). Initial termination of single boluses is governed by redistribution ( t 1 / 2 α = 15 minutes t_{1/2\alpha} = 15\text{ minutes} t 1/2 α ​ = 15 minutes ).

The Pitfall of Context-Sensitive Half-Time: When administered as a continuous infusion beyond 24 to 48 hours, peripheral tissue and adipose compartments become fully saturated. The context-sensitive half-time increases exponentially from minutes to > 200 – 300 minutes > 200\text{--}300\text{ minutes} > 200 – 300 minutes , causing drug accumulation, prolonged sedation, and delayed neurological wake-up exams.

Remifentanil

Ultra-short-acting ester-linked synthetic opioid agonist.

Organ-Independent Metabolism: Remifentanil is rapidly hydrolyzed by non-specific blood and tissue esterases into an inactive metabolite ( G I 90291 GI90291 G I 90291 , with 1 / 4600 th 1/4600\text{th} 1/4600 th parent potency). It does not depend on hepatic CYP enzymes or renal clearance.

Constant Context-Sensitive Half-Time: The context-sensitive half-time remains strictly 3 to 5 minutes 3\text{ to }5\text{ minutes} 3 to 5 minutes , completely independent of the duration of infusion (whether run for 2 hours or 10 days). This unique property enables immediate, crisp neurological assessments within minutes of halting the infusion. Because offset is immediate, adequate transition analgesia (e.g., hydromorphone or acetaminophen) must be established prior to discontinuation to prevent acute pain crises.

Hydromorphone

Semisynthetic hydrogenated ketone analog of morphine, 5 to 7 times more potent than morphine.

Undergoes hepatic glucuronidation into hydromorphone-3-glucuronide ( H 3 G H3G H 3 G ). Unlike morphine's metabolite morphine-6-glucuronide ( M 6 G M6G M 6 G ), H 3 G H3G H 3 G does not possess opioid agonist activity, avoiding morphine-6-glucuronide accumulation, while parent-drug sedation and respiratory depression still require monitoring in renal failure. However, high accumulation of H 3 G H3G H 3 G in severe renal failure may cause neuroexcitability (myoclonus, hyperalgesia). Hydromorphone triggers negligible histamine release compared to morphine, avoiding unpredictable arterial vasodilation.

Daily Spontaneous Awakening Trials (SAT) & Sedation Holidays

Daily spontaneous awakening trials consist of the coordinated, temporary cessation of continuous sedatives and opioids (or titration to minimal baseline analgesic levels) to allow the patient to awaken and demonstrate baseline neurologic function.

Mandatory Neuro-ICU Safety Screen

Prior to initiating an SAT, clinicians must systematically screen for contraindications. An SAT must NOT be performed in the presence of:

Active intracranial hypertension ( I C P > 20 mmHg ICP > 20\text{ mmHg} I CP > 20 mmHg or cerebral perfusion pressure instability) within the preceding 24 hours.

Active management of status epilepticus or burst suppression therapy.

Ongoing administration of neuromuscular blocking agents.

Targeted temperature management ( T T M TTM TTM ) during active cooling or controlled rewarming.

Severe respiratory failure: F i O 2 ≥ 0.70 FiO_2 \ge 0.70 F i O 2 ​ ≥ 0.70 or P E E P ≥ 10 cmH 2 O PEEP \ge 10\text{ cmH}_2\text{O} PEEP ≥ 10 cmH 2 ​ O , or active proning.

Active myocardial ischemia or refractory hemodynamic instability requiring escalating vasopressor support.

Warning

Interrupting sedation in patients with unstable intracranial dynamics, acute mass lesions, or non-compliant craniums risks catastrophic I C P ICP I CP rebound, herniation, or acute hypertensive rebleeding. Always verify that neuromonitoring parameters are stable and invasive lines are secured before attempting an SAT.

Clinical Impact

When passed safely, pairing daily SATs with Spontaneous Breathing Trials (SBT)—as central components of the ABCDEF bundle—reduces mechanical ventilation duration by an average of 2 to 3 days, decreases ICU length of stay, halves the rate of ICU delirium, reduces tracheostomy requirements, and significantly reduces 1-year mortality.